As Therapeutic Modalities Expand, Genomic Profiling Must Keep Pace
The boundaries of what’s considered “druggable” are shifting as advances in cell and gene therapies expand the possibilities for cancer treatment. Expanded insights can open new avenues for biomarker research and therapeutic discovery. The post As Therapeutic Modalities Expand, Genomic Profiling Must Keep Pace appeared first on GEN - Genetic Engineering and Biotechnology News .
As the scope of therapeutic options widens with the advent of cell and gene therapies, RNA treatments, targeted protein degradation, antibody-drug conjugates, and other modalities, the need for genomic profiling to keep pace becomes increasingly essential. This expansion of the therapeutic landscape necessitates a broader examination of disease mechanisms and targets that were previously deemed "undruggable."
The landscape of cancer-associated genetic variants is vast and not yet fully understood, even in well-studied cancers. This presents a significant opportunity for researchers to identify and investigate a wider range of genomic alterations, potentially leading to the development of transformative therapies. A strategic approach is to focus on specific patient cohorts with substantial unmet needs while conducting a more extensive search for variant discoveries.
Early genomic insights during development can enhance discovery, biomarker identification, and the creation of more effective therapies. Genomic testing remains a crucial component of personalized medicine, as diseases like cancer can be driven by both well-characterized and less common genetic alterations. Comprehensive genomic profiling (CGP) allows researchers to assess a broader range of cancer-associated genomic alterations, including single nucleotide variants, insertions, deletions, copy number variants, and specific gene fusions.
However, translating genomic insights into actionable therapeutic development faces several challenges. Establishing infrastructure to efficiently process large cohorts and extended study timelines is crucial. Sampled, an integrated analytical laboratory and biorepository, offers comprehensive genomic profiling capabilities, including sample collection, secure storage, processing, genomic profiling, and data analysis to support oncology research. To learn more about their services, visit sample.com and sample.com/gen.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
